Filing Flows

Filing Flows › Companies › Cumberland Pharmaceuticals › Cash flow

Cumberland Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$130K in Q2 2026 · $684K over twelve months

Operating cash flow$169K
Capital spending−$38K
Free cash flow+$130K

Analysis

In Q2 2026, Cumberland Pharmaceuticals generated $169K of operating cash flow and spent $38K on capital projects, leaving free cash flow of $130K. That is $687K less than in Q2 2025 ($817K).

Over the twelve months to Jun 30, 2026, operating cash flow was $746K; the largest uses were other investing ($5.7M), net borrowing (+) / repaid (−) ($5.2M), other financing ($1.9M); the cash balance fell by $12.2M.

Operating cash flow was $169K against net income of −$4.3M. The largest differences: payables +$1.5M, depreciation & amortization −$1.2M, receivables +$842K.

Free cash flow

Cumberland Pharmaceuticals: free cash flow by quarterCumberland Pharmaceuticals: free cash flow by quarter$460KQ3 2024$1.9MQ4 2024$3.9MQ1 2025$817KQ2 2025$163KQ3 2025$3KQ4 2025$387KQ1 2026$130KQ2 2026
Operating cash flow less capital spending.
Cumberland Pharmaceuticals: operating cash flow against capital spendingCumberland Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$476K$15KQ3 2024$1.9M$2KQ4 2024$3.9M$48KQ1 2025$844K$26KQ2 2025$187K$24KQ3 2025$3K−$1Q4 2025$387K$0Q1 2026$169K$38KQ2 2026
Latest (Q2 2026): Operating cash flow $169K, Capital spending $38K.

Capital allocation, year by year

Cumberland Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearCumberland Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $6.3MFY2021: Capital spending −$104KFY2021: Buybacks −$1.4M$6.3MFY2021FY2022: Operating cash flow $8.5MFY2022: Net borrowing $1.2MFY2022: Capital spending −$102KFY2022: Acquisitions −$13.5MFY2022: Buybacks −$1.1M$9.7MFY2022FY2023: Operating cash flow $6.1MFY2023: Net borrowing −$3.4MFY2023: Capital spending −$281KFY2023: Buybacks −$741K$6.1MFY2023FY2024: Operating cash flow −$612KFY2024: Capital spending −$66KFY2024: Buybacks −$579KFY2024FY2025: Operating cash flow $4.9MFY2025: Net borrowing −$10.0MFY2025: Shares issued $4.7MFY2025: Capital spending −$98KFY2025: Acquisitions −$2.5MFY2025: Buybacks −$263K$9.6MFY2025
Over these 5 years operating cash flow totalled $25.2M; the largest uses were acquisitions ($16.0M) and net borrowing ($13.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$3.9M
Debtnone
Net cash$3.9M

Cumberland Pharmaceuticals funds itself: free cash flow was $684K over the last twelve months, with $3.9M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Cumberland Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cumberland Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$7.1MNet borrowing (+) / repaid (−)−$5.2MOther investing−$1.9MOperating cash flow$169KOther financing−$146KCapital spending−$38K
Cumberland Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Cumberland Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$12.2MOther investing−$5.7MNet borrowing (+) / repaid (−)−$5.2MOther financing−$1.9MOperating cash flow$746KBuybacks−$71KCapital spending−$62K

From profit to cash

Cumberland Pharmaceuticals: net income to operating cash flow, Q2 2026Cumberland Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$4.3MDepreciation & amortization−$1.2MStock-based pay$78KReceivables$842KInventory−$704KPayables$1.5MPrepaid and other assets−$427KOther liabilities$557KOperating cash flow$169K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 2026154128817-535
Q4 20259261665-512
Q3 20251152861269-868
Q2 202587166619-366
Q1 202585256879-538
Q4 2024101198604-305
Q3 2024116306854-432

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$169K−$38K——−$5.2M—$7.1M$130K
Q1 2026$387K——−$61K——$437K$387K
Q4 2025$3K$1−$1.0M———$3.8M$3K
Q3 2025$187K−$24K−$612K−$10K——$891K$163K
Q2 2025$844K−$26K$326K−$7K——−$979K$817K
Q1 2025$3.9M−$48K−$1.2M−$246K−$10.0M$4.7M$2.9M$3.9M
Q4 2024$1.9M−$2K—−$98K−$815K—−$499K$1.9M
Q3 2024$476K−$15K—−$99K——−$128K$460K

Cumberland Pharmaceuticals: income statement and cash flow

Cumberland Pharmaceuticals, Q2 2026: revenue $8.8M (-19% year over year), operating margin -35.9%. The chart follows the revenue to costs, profit and cash.

Cumberland Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.